Loading clinical trials...

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE1

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours

NCT00750841•AstraZeneca

View on ClinicalTrials.gov

Summary

Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.

Eligibility

Age

18 - 130 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Written informed consent
•Prostate cancer), which is refractory to standard therapies or for which no standard therapy exists.
•Estimated life expectancy of at least 8 weeks
•WHO performance status (PS) 0-2.

Exclusion Criteria

•Unstable brain/meningeal metastases
•Biochemistry/haematology results outside of required ranges
•History of significant GI impairment
•Inadequate bone marrow reserve

Locations (6)

Research Site

Edmonton, Alberta, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Dundee, United Kingdom

Research Site

Glasgow, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Key Dates

Start Date

September 9, 2008

Primary Completion Date

July 30, 2009

Completion Date

December 31, 2026

Last Updated

February 23, 2026

Enrollment

ACTUAL participants

Conditions

Solid Tumors

Interventions

cediranib

DRUG

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

View study

RECRUITINGNA

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

NCT06658951

HER2-positive Advanced Malignant Solid Tumors

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

A Study of ASP1002 in Adults for Treatment of Solid Tumors

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors